Serial 88984103
Live / Registered — Registered (as of 24 May 2022)
What this means for you
Registered since 24 May 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88984103
- Registration number
- 6740135
- Mark type
- Design / logo
- Filed
- 21 Jun 2019
- Published for opposition
- 20 Aug 2019
- Registered
- 24 May 2022
- Attorney of record
- Karen Feisthamel
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of viral, oncological, respiratory, and immune system related diseases and disorders; Pharmaceutical preparations and substances for the treatment of infectious diseases, pharmaceutical products for the treatment of viral and infectious diseases, and for the treatment of cancer
- Class 042 — Scientific and technological services: Research and development services in the field of antibodies; providing information on the subject of scientific research in the field of biochemistry and biotechnology; providing medical research and scientific research information in the field of oncology; biotechnology research; research and development in the pharmaceutical and biotechnology fields
Owner
- IGM Biosciences, Inc., Mountain View, CA, US
- IGM Biosciences, Inc., Mountain View, CA, US
- IGM Biosciences, Inc., Mountain View, CA, US
Prosecution history
- 25 May 2022 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 May 2022 — REGISTERED-PRINCIPAL REGISTER
- 20 Apr 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 19 Apr 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 19 Apr 2022 — NOTICE OF DESIGN SEARCH CODE E-MAILED
- 18 Apr 2022 — STATEMENT OF USE PROCESSING COMPLETE
- 31 Mar 2022 — USE AMENDMENT FILED
- 18 Apr 2022 — DIVISIONAL PROCESSING COMPLETE
- 31 Mar 2022 — DIVISIONAL REQUEST RECEIVED
- 15 Apr 2022 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 31 Mar 2022 — TEAS REQUEST TO DIVIDE RECEIVED
- 31 Mar 2022 — TEAS STATEMENT OF USE RECEIVED
- 05 Oct 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 01 Oct 2021 — SOU EXTENSION 4 GRANTED
- 01 Oct 2021 — SOU EXTENSION 4 FILED